Add time:07/16/2019         Source:sciencedirect.com

BackgroundPlasma androgen receptor (AR) copy number status has been identified as a potential biomarker of response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel or the AR-targeted therapies abiraterone or enzalutamide. However, the relevance of plasma AR status in the context of cabazitaxel therapy is unknown.

We also recommend Trading Suppliers and Manufacturers of (aR)-2,2'-Dihydroxy-1,1'-binaphthalene-3,3'-dicarboxylic acid (cas 18531-92-5). Pls Click Website Link as below: cas 18531-92-5 suppliers